Compare Charles River Laboratories Intl. Inc (CRL) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Rivian (RIVN) trades at $16.015, down 2.29% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $5.0B in 2024 to $5.4B in 2025, though net losses persist at -$3.65B. Recent R2 vehicle launches and raised 2026 delivery guidance to 65,000-70,000 vehicles indicate operational progress. Analyst consensus is mixed with 48% buy ratings and a $18.70 price target, suggesting 17% upside potential from current levels.

Rivian presents a high-risk growth opportunity with significant cash burn ($1.72B net outflow in 2025) but improving margin trends. The R2 ramp-up and Uber partnership offer catalysts, though execution risks and EV market competition remain concerns. With negative profitability metrics and substantial debt, the stock suits investors comfortable with early-stage company volatility seeking EV market exposure.